1Q24 Investor Update
INVESTMENT IN SEED
GENETICS & THCV
●
In May of 2023, Organigram made its first investment into the U.S cannabis market by issuing a
strategic convertible loan to Phylos
●
●
●
Phylos will enable Organigram to accelerate the launch of products containing THCV in the Canadian
market - THCV provides consumer with a differentiated experience compared to THC (appetite
suppression, no cognitive impairment, energizing and focusing effect)
Organigram will significantly reduce operating costs by transitioning its flower production from cloning
to seed which reduces the need for cloning, propagation, and pre-vegetation
Seed-based cultivation using "F1" seeds produces more robust and consistent plants, yielding
consistent cannabinoid and terpene profiles, uniform size, and other desirous qualities.
In Q1 F2024, due to the achievement of THCV concentration and aroma specific milestones from F1 seeds,
Organigram advanced the second tranche of US$2.75 million to Phylos for a total current investment of
US $6.0 million in senior secured convertible loans
First seed-based room planted in Q1 F2024 to begin transition of a portion of Moncton facility to growing
from more cost-effective and consistent F1 seeds
ORGANIGRAM
Po
phylos
238 18.5-View entire presentation